38results about How to "Inhibit lipid accumulation" patented technology

A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I):wherein Z is C═O or a covalent bond; Y is H or O(C1–C4)alkyl, R1 and R2 are individually (C1–C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H or together with R3 is —CH2—CH2— or —S—, R5 is I, O(C1–C4)alkyl or H, and R6 is I, O(C1–C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to activate or stimulate production of TGF-beta to treat and / or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene and salts thereof. Further provided is a method for identifying a compound that is a TGF-beta activator or production stimulator is provided. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifen or structural analogs thereof, including compounds of formula (I).

A pharmaceutical composition is provided having at least one kind to be selected from the group consisting of a lactoferrin group protein having lactoferrin and conalbumin, and an enzymatically decomposed product of the lactoferrin group protein having peptides corresponding to lactoferricin and lactoferricin of conalbumin as an active ingredient. The composition of the present invention can be used as an agent for improving lipid metabolism. Further, it is useful for treating hypercholesterolemia, hyper-neutral lipidemia, hyper-low density lipoprotein (LDL) cholesterolemia, hypo-high density lipoprotein (HDL) cholesterolemia, obesity, fatty liver and cholesterol gallstone and lifestyle-related diseases such as severe obesity, hyperlipidemia, hypertension and type II diabetes. The composition of the present invention can improve basal metabolic rate.

The present invention provides a pharmaceutical composition having at least one kind to be selected from the group consisting of a lactoferrin group protein comprising lactoferrin and conalbumin, and an enzymatically decomposed product of the lactoferrin group protein comprising peptides corresponding to lactoferricin and lactoferricin of conalbumin an active ingredient. The composition of the present invention can be used as an agent for improving lipid metabolism. Further, it is useful for treating hypercholesterolemia, hyper-neutral lipidemia, hyper-low density lipoprotein (LDL) cholesterolemia, hypo-high density lipoprotein (HDL) cholesterolemia, obesity, fatty liver and cholesterol gallstone and lifestyle-related diseases such as severe obesity, hyperlipidemia, hypertension and type II diabetes. The composition of the present invention can improve basal metabolic rate.

Cyclodextrin compound therapeutics to reduce age-related non-bisretinoid lipofuscin in a patient having a buildup of same, said method comprising administering 2-hydroxypropyl-β-cyclodextrin, or its derivatives, or β-cyclodextrin or its derivatives, or α-cyclodextrin or its derivatives, or γ-cyclodextrin or its derivatives in an amount effective to reduce non-bisretinoid lipofuscin levels. The methods include treating and / or preventing aging of the skin, muscle and other tissues and organs, which may result in increased life-span or health-span.

The invention discloses new dihydrogen homoisoflavonoid, and a preparation method and application thereof. The new dihydrogen homoisoflavonoid is separated to extract polygonatum sibiricum. Experiments prove that the dihydrogen homoisoflavonoid can remarkably inhibit lipid accumulation in Hep-G2 cells, also can remarkably reduce the triglyceride (TG) content and the total cholesterol (TC) content of the cells, is more excellent that a positive control medicine simvastatin in the aspect of reducing the TG, and has excellent blood fat-reducing activity. The discovery of the new dihydrogen homoisoflavonoid provides a new lead compound for developing a new blood fat-reducing medicine, and good development and application prospect is achieved. The preparation process is simple, stable and reliable, the purity of the compound is high (above 98 percent), industrialized popularization is facilitated, a new approach is opened up for research and development of the blood fat reducing medicines, and good social and economic benefits are achieved.

The present invention relates to edible compositions for the maintenance of normal liver function comprising zinc, 1-deoxynojirimycinand α-lipoic acid.

The present invention relates to a pharmaceutical or a food additive composition comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases or obesity, and a method for the treatment of lipid-related cardiovascular diseases or obesity comprising administering the pharmaceutical composition to a subject in need of the same. The Viola Herba extract, or the extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. of the present invention is shown to be effective in reducing body weight, body fat, total cholesterol in blood, and lowering blood pressure, and thus can be used for effective prevention or treatment of lipid-related cardiovascular diseases or obesity.

The present invention relates to a fat absorption inhibitor containing a chestnut skin extract, and a food and drink containing that fat absorption inhibitor. The present invention can therefore provide a fat absorption inhibitor, and a food and drink using the same, that can be obtained from waste products following primary use, inhibit increases in lipids such as blood neutral fats by inhibiting absorption of dietary lipids, and in turn are effective in preventing accumulation of lipids, have superior suitability for continuous ingestion without having an impact on flavor, and do not require a complex production process.

A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

The invention belongs to the technical field of biological polypeptides, and particularly relates to a polypeptide applied to inhibition of intracellular lipid accumulation and a synthesis method thereof. The amino acid sequence of the polypeptide is as shown in a sequence table SEQ ID NO.1. The polypeptide has relatively high target affinity and high activity, and can show remarkable high activity under very low dosage and concentration, inhibit binding of lectin and sterol O-acyltransferase by exerting competition on the lectin and reduce the activity of the sterol O-acyltransferase, so as to achieve functions of controlling physiological metabolism in organisms, such as relieving lipid accumulation in hepatocytes, resisting tumor generation, assisting anti-cancer drugs in inhibiting tumor growth and the like. The synthetic process of the polypeptide is simple, the molecular weight of the polypeptide is small, the artificial synthesis efficiency is high, the difficulty of product purification in each step is greatly reduced through a solid-phase synthesis method, and the process is automatic, easy to control and low in cost.

A scavenger receptor A expression down-regulator and a drug for preventing or treating arteriosclerosis which contain, as the active ingredient, a C-terminal globular domain of adiponectin, adiponectin, or a gene encoding the domain or adiponectin. According to the present invention, there is provided a preventive or therapeutic agent capable of directly preventing intimal thickening, which constitutes an essential feature of arteriosclerosis. This effect can be attained through arresting the onset and development of arteriosclerosis by reducing the expression level of scavenger receptor A in arterial walls and preventing lipid buildup in macrophages.

The invention belongs to the technical field of feed processing, and particularly relates to a golden pomelo young fruit polysaccharide-containing grouper feed and a preparation method thereof. The golden pomelo young fruit polysaccharide-containing grouper feed not only can improve the oxidation resistance and immunity of pearl gentian groupers, but also can inhibit lipid accumulation of the pearl gentian groupers and improve the liver structure and liver pathological damage degree, and is free of toxic and side effects and environmentally friendly. Meanwhile, the grouper feed containing the golden pomelo young fruit polysaccharide is low in vitamin loss rate when being put into a water body, the vitamin content in the feed can be well maintained, the vitamin absorption of the pearl-gentian grouper is ensured, and the growth and reproduction of the grouper are more facilitated.

A method for preventing and / or treating the formation of liver injury resulting from lipid accumulation in hepatocytes and / or inflammation of liver tissue and / or fibrosis in liver tissue and / or Non-Alcoholic Steatohepatitis (NASH) and / or alcoholic consumption and / or other toxic causes of liver injury by is performed by administering of iso-alpha-acid. An oral composition may be used.

The invention relates to a human leukocyte protease inhibitory factor as well as recombinant preparation and an application thereof, which belong to the field of biological medicines. The amino acid sequence contained in the human leukocyte protease inhibitory inhibitor is as follows: (1) an amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; (2) an amino acid sequence obtained by connecting a label to the N end or / and C end of the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; and (3) an amino acid sequence which is obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence shown in SEQ ID NO: 1 and SEQ ID NO: 2 or SEQ ID NO: 3 and has the activity of the human leukocyte protease inhibitory factor. The preparation method comprises the following steps: constructing plasmids, carrying out inducible expression to obtain fusion protein, purifying, and carrying out renaturation concentration. The protein provided by the invention has important application in preparation of drugs for treating metabolic diseases, and can reduce weight, inhibit increase of adipose tissue weight and inhibit liver fatty degeneration.

The invention provides an application of rosustat in a medicine for inhibiting acute alcoholic fatty liver. Roxasstat can significantly inhibit liver injury and lipid accumulation caused by acute alcohol. According to the mechanism, rosustat plays a role in inhibiting mouse liver lipid accumulation mainly by regulating and controlling the expression of lipid synthesis key genes. The medicine is expected to become an effective medicine for clinically treating the alcoholic fatty liver.

An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and / or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and / or a medium-chain triglyceride) for inhibiting neutral lipid accumulation.

The invention discloses application of malonic-acid-modified fullerene C70 in preparation of a medicine for treating the non-alcoholic fatty liver disease. The medicine that uses the C70-malonic acidderivative as the active ingredient and is used for preventing, relieving and / or treating the non-alcoholic fatty liver disease and related diseases has the following advantages: firstly, the pharmacodynamic effect is obvious, the C70-malonic acid derivative can obviously inhibit lipid accumulation in primary hepatocytes of mice and obvious changes can be seen in 10 micrometers; in addition, the C70-malonic acid derivative also has an obvious improvement effect on liver lipid accumulation and fibrosis generated by HFHC diet induction; secondly, the malonic-acid-modified fullerene C70 can effectively reduce the damage of a carbon cage in a fullerene modification process, so that the pharmacodynamic activity of the fullerene body is better retained; and thirdly, the C70-malonic acid derivative has a determined molecular structure, problems that other water-soluble fullerene derivatives have no determined structure and are difficult in quality control are solved, and the patent medicine is realized conveniently.

The present invention is related to a pharmaceutical composition and a dietary supplement for treating and preventing obesity, containing a wheatgrass extract as an active ingredient, it has been ascertained that the wheatgrass extract shows excellent anti-obesity effects such as significant inhibition of weight gain caused by a high fat diet, or lowering of neutral lipid levels in blood in a high fat diet-induced animal model. The wheatgrass extract of the present invention can be useful as a pharmaceutical composition and a dietary supplement for preventing and treating obesity.

The invention discloses application of sorafenib to preparing a medicine for preventing, alleviating and / or treating fatty liver and related diseases, and belongs to novel application of the medicineof the sorafenib. The medicine taking the sorafenib as the active ingredient and used for preventing, alleviating and / or treating fatty liver and related diseases has the following advantages: 1, thesorafenib belongs to a medicine approved by U.S.FDA, and therefore, the existing huge toxicity and dosage data of the medicine are utilized, and a large amount of time and a large number of financialresources are saved; and 2, the curative effect is obvious, the sorafenib obviously inhibits the accumulation of lipid in a cell L02, and the obvious change is seen when the pretreatment concentrationof the sorafenib is 2 [mu]mol; when the pretreatment concentration of the sorafenib is 6 [mu]mol, the sorafenib is detected to obviously inhibit the accumulation of the lipid in the primary hepatocyte of a mouse; and in addition, the sorafenib has an obvious effect of inhibiting the accumulation of the lipid caused by the induction of the HFHC (High Fat and High Cholesterol) diet. The sorafenib has a broad application prospect in the medical field.

A method for treating or preventing cardiovascular pathologies by administering a compound of the formula (I): wherein Z is C═O or a covalent bond; Y is H or O(C1-C4)alkyl, R1 and R2 are individually (C1-C4)alkyl or together with N are a saturated heterocyclic group, R3 is ethyl or chloroethyl, R4 is H, R5 is I, O(C1-C4)alkyl or H and R6 is I, O(C1-C4)alkyl or H with the proviso that when R4, R5, and R6 are H, R3 is not ethyl; or a pharmaceutically acceptable salt thereof, effective to elevate the level of TGF-beta to treat and / or prevent conditions such as atherosclerosis, thrombosis, myocardial infarction, and stroke is provided. Useful compounds include idoxifene, toremifene or salts thereof. Further provided is a method for identifying an agent that elevates the level of TGF-beta. Another embodiment of the invention is an assay or kit to determine TGF-beta in vitro. Also provided is a therapeutic method comprising inhibiting smooth muscle cell proliferation associated with procedural vascular trauma employing the administration of tamoxifin or structural analogs thereof, including compounds of formula (I).

The invention provides Lactobacillus paracasei B111H and its application in metabolic syndrome, and relates to the technical field of microorganisms and its application. The strain of Lactobacillus paracasei is preserved in the General Microbiology Center of the China Committee for the Collection of Microorganisms, with the preservation number: CGMCC No: 22184; the preservation time is: April 14, 2021. Lactobacillus paracasei of the present invention is isolated and screened from human feces, has the effect of significantly inhibiting lipid accumulation in liver cells, reducing body weight and blood lipid levels, and improving hepatic steatosis. The occurrence of liver has important application significance. The discovery of the strain provides a new microbial resource for lipid-lowering foods or medicines.

The invention discloses new dihydrogen homoisoflavonoid, and a preparation method and application thereof. The new dihydrogen homoisoflavonoid is separated to extract polygonatum sibiricum. Experiments prove that the dihydrogen homoisoflavonoid can remarkably inhibit lipid accumulation in Hep-G2 cells, also can remarkably reduce the triglyceride (TG) content and the total cholesterol (TC) content of the cells, is more excellent that a positive control medicine simvastatin in the aspect of reducing the TG, and has excellent blood fat-reducing activity. The discovery of the new dihydrogen homoisoflavonoid provides a new lead compound for developing a new blood fat-reducing medicine, and good development and application prospect is achieved. The preparation process is simple, stable and reliable, the purity of the compound is high (above 98 percent), industrialized popularization is facilitated, a new approach is opened up for research and development of the blood fat reducing medicines, and good social and economic benefits are achieved.

Proposed is a Geumhwagyu extract as an active ingredient. The Geumhwagyu extract of the present disclosure inhibits the differentiation of pre-adipocytes by inducing the degradation of CEBP-α and inhibits the expression of CEBP-α, PPARγ, Perilipin-1, Adiponectin, FABP4, etc., to suppress the accumulation of lipids in adipocytes. It can be easily used as a composition for preventing or managing obesity by inhibiting it and lowering the content of TG (Triacylglycerol) to show anti-obesity activity.

The present invention relates to a pharmaceutical composition, a health functional food, and a feed composition for the prevention, improvement, or treatment of non-alcoholic liver disease or insulin resistance comprising ginsenoside F2. The pharmaceutical composition according to the present invention comprising ginsenoside F2 can inhibit the adipogenesis and lipid accumulation in the liver, improve insulin sensitivity, inhibit the expression of inflammatory cytokines such as TNF-α, IL-β, and IL-6 in the Kupffer cell, inhibit the expression of endocannabinoid synthase, thus capable of effectively preventing or treating non-alcoholic liver disease or insulin resistance.

The invention relates to human leukocyte protease inhibitory factor and its recombinant preparation and application, belonging to the field of biomedicine. The amino acid sequence contained in human leukocyte protease inhibitor is: (1) the amino acid sequence shown by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3; (2) in SEQ ID NO: 1, SEQ ID NO: ID NO: 2 or the amino acid sequence obtained by connecting the N-terminal or / and C-terminal tag of the amino acid sequence shown in SEQ ID NO: 3; (3) in SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3 The amino acid sequence shown is substituted, deleted or added with one or several amino acids and has the activity of the human leukocyte protease inhibitor. The preparation method is to first construct the plasmid, then induce expression to obtain the fusion protein, and then perform renaturation and concentration after purification. The protein in the invention has important applications in the preparation of medicines for treating metabolic diseases, and can reduce body weight, inhibit the increase of fat tissue weight, and inhibit hepatic fatty degeneration.

The invention provides Bifidobacterium pseudocatenatum and application thereof in metabolic syndrome, and relates to the field of microorganisms. The preservation number of the Bifidobacterium pseudocatenatum is CGMCC No.22185, the Bifidobacterium pseudocatenatum is preserved in China General Microbiological Culture Collection Center on April 14, 2021, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing. According to the Bifidobacterium pseudocatenatum, the accumulation of liver cell lipid can be significantly inhibited, the body weight and the blood fat level can be reduced, the liver fatty degeneration can be further improved, and the important application significance can be provided for the alleviation of the occurrence of hyperlipidemia, obesity and fatty liver.

The invention belongs to the field of marine medicines, and in particular relates to an oligosaccharide containing D-galactose and L-galactose and its derivatives and its application as a drug or health product for improving mitochondrial function and preventing insulin resistance-related diseases. Using red algal polysaccharides containing D‑ / L‑galactose as raw materials, degrade them by physical methods, chemical methods, biological enzyme methods or any combination of the above methods to prepare galactooligosaccharides and their derivatives with different degrees of polymerization, Its molecular skeleton contains D‑galactose and L‑galactose and their derivatives. The raw material of the product of the present invention is derived from red algae polysaccharide, which has the advantages of rich resources, simple preparation process, high safety, clear target and easy industrialization. The development field of special medical food such as blood fat and blood pressure lowering has broad application prospects.